论文部分内容阅读
目的分析家属协同护理模式在肺炎支原体感染患儿中的应用效果。方法选取2015年7月—2016年9月应城市人民医院收治的肺炎支原体感染患儿150例,随机分为对照组和观察组,每组75例。在常规药物治疗基础上,对照组患儿给予常规护理干预,观察组患儿在对照组基础上采用家属协同护理模式。比较两组患儿退热时间、咳痰消失时间、平喘时间、咳嗽消失时间、住院时间、住院费用、临床疗效、不良反应发生情况及家属护理满意度。结果观察组患儿退热时间、咳痰消失时间、平喘时间、咳嗽消失时间及住院时间短于对照组,住院费用少于对照组(P<0.05)。观察组患儿临床疗效优于对照组(P<0.05)。观察组患儿不良反应发生率低于对照组(P<0.05)。观察组患儿家属对护理满意度优于对照组(P<0.05)。结论家属协同护理模式有助于提高肺炎支原体感染患儿临床疗效,改善患儿临床症状,提高家属护理满意度,减少不良反应的发生。
Objective To analyze the application effect of cooperative nursing in family members of children with Mycoplasma pneumoniae infection. Methods 150 children with Mycoplasma pneumoniae infection from July 2015 to September 2016 in Yingcheng People’s Hospital were randomly divided into control group and observation group with 75 cases in each group. On the basis of conventional drug treatment, children in the control group were given routine nursing interventions. The children in the observation group were treated with the family-based collaborative nursing model on the basis of the control group. The time of fever, the disappearance of expectoration, the time of asthma relief, the disappearance of cough, the length of stay, the hospitalization cost, the clinical efficacy, the incidence of adverse reactions and the satisfaction of family nurses were compared between the two groups. Results The observation group patients with fever, sputum disappear time, asthma time, cough disappear time and hospital stay shorter than the control group, hospitalization costs less than the control group (P <0.05). The clinical efficacy of the observation group was better than that of the control group (P <0.05). The incidence of adverse reactions in observation group was lower than that in control group (P <0.05). Family members of the observation group had better nursing satisfaction than the control group (P <0.05). Conclusion Collaborative nursing model helps to improve the clinical efficacy of children with Mycoplasma pneumoniae infection, improve the clinical symptoms of children, improve family nursing satisfaction and reduce the incidence of adverse reactions.